NewGenIvf (NIVF) EBITDA Margin (2024 - 2025)
NewGenIvf (NIVF) posted quarterly EBITDA Margin of 531.42% for Q4 2025, down 52849.0% YoY from N/an in Q4 2024, and down 141.57% sequentially from 1278.22% in Q3 2025.
NewGenIvf (NIVF) EBITDA Margin (2024 - 2025) Analysis & Trends
NewGenIvf has disclosed EBITDA Margin across 2 years of filings, most recently posting 531.42% for Q4 2025.
- In Q4 2025, EBITDA Margin fell 52849.0% year-over-year to 531.42%; the TTM figure through Dec 2025 stood at 157.23% (changed N/A YoY), while the FY2025 annual figure was 201.12%, up 20925.0% from the prior year.
- EBITDA Margin declined to 531.42% in Q4 2025, from 1278.22% in the prior quarter.
- Over the last five years, EBITDA Margin for NIVF reached as high as 1278.22% in Q3 2025 and fell as low as 531.42% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | HCA Healthcare | 87.94 Bn | 90.32 Bn | 16.26 Bn | -2.96% |
| 2 | Chemed | 18.08 Bn | 18.07 Bn | 215.76 Mn | 15.04% |
| 3 | Tenet Healthcare | 16.59 Bn | 15.76 Bn | 4.41 Bn | 24.14% |
| 4 | Davita | 15.37 Bn | 16.23 Bn | 1.07 Bn | 14.11% |
| 5 | Encompass Health | 10.07 Bn | 10.70 Bn | 1.34 Bn | 3.76% |
| 6 | Ensign | 9.52 Bn | 8.93 Bn | 293.37 Mn | 8.99% |
| 7 | Universal Health Services | 9.19 Bn | 9.15 Bn | 3.21 Bn | 11.19% |
| 8 | Pacs | 6.96 Bn | 6.72 Bn | 345.96 Mn | 8.45% |
| 9 | Ww International | 6.14 Bn | 5.98 Bn | -149.29 Mn | 17.01% |
| 10 | NewGenIvf | 25,304.95 | -1.41 Mn | 524,025.00 | -531.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -531.42% |
| Sep 30, 2025 | 1,278.22% |
| Dec 31, 2024 | -2.93% |
| Sep 30, 2024 | -14.14% |